Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic ...

Opus Genetics (IRD) announced that a presentation featuring the LYNX-1 Phase 3 study of Phentolamine Ophthalmic Solution 0.75% in patients with ...

Opus also announced that enrollment in the LYNX-2 pivotal Phase 3 trial, evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of visual loss in low light conditions associated with ...

Opus Genetics (IRD) said that the FDA has granted Fast Track designation for Phentolamine Ophthalmic Solution 0.75% as a potential treatment for chronic night driving impairment and debilitating ...

The Fast Track designation is supported by the ongoing randomized, double-masked phase 3 LYNX-2 trial. The Food and Drug Administration (FDA) has granted Fast Track designation to phentolamine ...

Enrollment is complete in the VEGA-3 phase 3 clinical trial of phentolamine for presbyopia. The FDA granted fast track designation to phentolamine ophthalmic solution 0.75% to treat significant ...

(RTTNews) - Opus Genetics, Inc. (IRD) announced Wednesday that its Phentolamine Ophthalmic Solution 0.75 percent has been granted Fast Track designation by the U.S. FDA. This designation is for ...

(NASDAQ:IRD), a $33 million market cap biotech firm specializing in ophthalmic disorders, has recently completed enrollment for its VEGA-3 Phase 3 trial, which tests Phentolamine Ophthalmic ...